Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Dermatologic 1

Conditions

Ovarian Neoplasms 104Breast Neoplasms 76Fallopian Tube Neoplasms 47Multiple Myeloma 32Carcinoma, Ovarian Epithelial 27Neoplasms 23Lymphoma 16Sarcoma 13Triple Negative Breast Neoplasms 12Recurrence 12Neoplasm Metastasis 12Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 8Hodgkin Disease 8Neoplasms, Plasma Cell 6Prostatic Neoplasms 5Burkitt Lymphoma 5Solid Tumors 4Sarcoma, Kaposi 4Sarcoma, Ewing 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leiomyosarcoma 4Endometrial Neoplasms 4Carcinoma 4Breast Neoplasms, Male 4Uterine Cervical Neoplasms 3Rhabdomyosarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × liposomal doxorubicin × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

University of California, San Francisco

Phase 2 Terminated
21 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03952572 2019-05-16

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peking University

Phase 3 Unknown
244 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03023358 2017-01-18

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Nanfang Hospital, Southern Medical University

Phase 3 Unknown
174 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡